But did -- in a scientific sense -- STAR*D treatment work at all? While the Washington Post did point out that STAR*D reveals, "Antidepressants fail to cure the symptoms of major depression in half of all patients with the disease even if they receive the best possible care, " the following went unreported by all major media outlets:
For STAR*D, NIMH hired researchers with extensive financial ties to the pharmaceutical companies that manufacture the antidepressants that were studied.
STAR*D 's scientific methodology were astonishingly substandard, especially its failure to include a placebo control group. In other antidepressant studies, patients treated with sugar-pill placebos have done as well or better than STAR*D results.
There were two levels or stages -- to STAR*D. In the first stage, all depressed patients received the antidepressant Celexa. In the second stage, Celexa-treated patients who failed to have remission of depression symptoms were assigned to several other treatment modes, including the substitution of Celexa with another antidepressant, either Effexor, Wellbutrin, or Zoloft; or Celexa was augmented with either Wellbutrin or Buspar (an antianxiety drug).
The pharmaceutical companies that manufacture Celexa, Effexor, Wellbutrin, Zoloft, and Buspar were well-acquainted with STAR*D researchers. The two lead STAR*D investigators Dr. A. John Rush and Dr. Madhukar H. Trivedi receive consulting fees from or served on the advisory boards for Forest Pharmaceuticals (Celexa), Wyeth-Ayerst Laboratories (Effexor), and Bristol-Myers Squibb (Buspar); while Dr. Rush has such a relationship with GlaxoSmithKline (Wellbutrin) and Dr. Tiveldi has such a relationship with Pfizer (Zoloft); and Dr. Rush has an equity interest in Pfizer. Both have received speaker fees from Forest Pharmaceuticals; Dr. Rush has received speaker fees from GlaxoSmithKline; and Dr. Trivedi has received speaker fees from Wyeth-Ayerst Laboratories and Bristol-Myers Squibb. The drugs used in STAR*D were furnished at no cost by their manufacturers.
This absence of a placebo control in a treatment effectiveness study is astonishing because it has long been known that sugar pills, other placebos, or any treatment -- including bloodletting -- are routinely reported by some patients as curing their depression. And so by the 1940s, a scientifically respectable investigation of a drug 's effectiveness required a placebo control to which the effects of the hypothesized therapeutic drug could be compared.
Today it is well known in the scientific community from several other antidepressant studies that a placebo does as well or better than Celexa 's 27.5 percent success rate in STAR*D. An April 2002 Journal of American Medical Association (JAMA) study compared the effectiveness of the antidepressant Zoloft, the herb St. John 's wort, and a placebo in depressed patients. In the JAMA study, the placebo-treated patients had a 31.9 percent rate of remission of symptoms (Zoloft 's remission rate was 24.8 percent and St. John 's wort 's remission rate was 23.9 percent). NIMH and STAR*D researchers ignored the superior placebo remission rate in the JAMA study.
Instead, NIMH and STAR*D researchers trumpeted the impressiveness of remission rates given how especially depressed the STAR*D patients were. However, the patients in the JAMA study were actually more depressed then those patients in the STAR*D study. The STAR*D and JAMA studies utilized the identical measure of depression, the Hamilton Rating Scale for Depression (HRSD-17), in which a score can range from 0 to 52, with higher scores indicating more depression symptoms. The criteria for inclusion in the JAMA study was score of 20 or higher, while in STAR*D it was only 14 or higher. (The criteria score for symptom remission was almost the same in both studies, 8 or less in JAMA, 7 or less in STAR*D).
While the Celexa remission rate in the first stage of STAR*D study was highly disappointing compared to placebo results in other antidepressant studies, NIMH (which rounded up the Celexa 27.5 percent remission rate to "about a third ") described it as "particularly good results. " This would be like saying that the New York Knicks had "particularly good results " scoring 88 points while neglecting to say that their opponent scored 100 points, or, even more analogous, staging the basketball game without providing the Knicks an opponent.
The second stage of STAR*D provided a second level of treatment for those depressed patients who failed to respond favorably to Celexa. It lasted 14 weeks and was reported in the March 23, 2006 New England Journal of Medicine. Among Celexa nonresponders, of those assigned another antidepressant, 21 percent had a remission of symptoms; of those who had their Celexa augmented with another drug, 30 percent had a remission of symptoms. As in stage one, there was no placebo control. And again, it is known from other antidepressant studies that had there had been a placebo control in stage two, the control would likely have done as well or better than STAR*D results.
It gets worse. Depressed people who likely would have been uncured by STAR*D were excluded from the STAR*D study. And it is conceivable that had the STAR*D subjects been sampled from the entire population, STAR*D result may have been worse than a 50 percent remission rate.
One important group of excluded subjects was actually discussed in the NIMH press release, "For example, people were not eligible for the study if they had already been treated with an adequate dose for adequate period of time with one or more of the treatments that were part of the first two STAR*D treatment steps. " Thus, NIMH 's 50 percent remission rate is analogous to concluding, "A study shows that X antibiotic is effective for 50 percent of those with Y infection, " when in fact the researchers had excluded from the study all those whom had previously taken X antibiotic for Y infection but had been uncured by it.